Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and ...
Though barzolvolimab displayed what one analyst described as the best efficacy results to date against chronic skin hives, ...
Trial participants mostly kept their weight down after switching from a weekly shot to less frequent dosing — findings that ...
Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results